Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT06434961 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06434961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06434961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Lead sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2024
Completion date
November 11, 2025
Enrollment
498 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism